U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07426757) titled 'An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers' on Feb. 16.
Brief Summary: This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.
The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess...